A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled AZD8683 After Single Ascending Doses in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 03 Mar 2010
At a glance
- Drugs AZD 8683 (Primary)
- Indications Obstructive airway disorders
- Focus Adverse reactions
- Sponsors AstraZeneca
- 03 Mar 2010 Actual patient number (130) added as reported by ClinicalTrials.gov.
- 03 Mar 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 03 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.